Bioinformatics design of a peptide vaccine containing sarcoma antigen NY-SAR-35 epitopes against breast cancer and evaluation of its immunological function in BALB/c mouse model

Samman, Nour; Mohabatkar, Hassan; Behbahani, Mandana; Ganjlikhani Hakemi, Mazdak

Bioinformatics design of a peptide vaccine containing sarcoma antigen NY-SAR-35 epitopes against breast cancer and evaluation of its immunological function in BALB/c mouse model

dc.contributor.author	Samman, Nour
dc.contributor.author	Mohabatkar, Hassan
dc.contributor.author	Behbahani, Mandana
dc.contributor.author	Ganjlikhani Hakemi, Mazdak
dc.date.accessioned	2024-07-02T05:33:42Z
dc.date.available	2024-07-02T05:33:42Z
dc.date.issued	2024
dc.department	İstanbul Medipol Üniversitesi, Rektörlük, Rejeneratif ve Restoratif Tıp Araştırmaları Merkezi (REMER)
dc.department	İstanbul Medipol Üniversitesi, Rektörlük, Sağlık Bilim ve Teknolojileri Araştırma Enstitüsü
dc.description.abstract	The development of a cancer vaccine has become an essential focus in the field of medical biotechnology and immunology. In our study, the NY-SAR-35 cancer/testis antigen was targeted to design a novel peptide vaccine using bioinformatics tools, and BALB/c mice were used to evaluate the vaccine's immunological function. This evaluation involved assessing peptide-specific IgG levels in the serum via ELISA and measuring the levels of IFN-?, IL-4, and granzyme B in the supernatant of cultured splenocytes. The final vaccine construct consisted of two T lymphocyte epitopes linked by the AAY linker. This construct displayed high antigenicity, non-allergenicity, non-toxicity, stability, and ability to induce IFN-? and IL-4. It showed stable dynamics with both human MHC-I and II molecules, as well as mouse MHC-II molecules, and revealed strong Van der Waals and electrostatic energies. Emulsifying our peptide vaccine in incomplete Freund's adjuvant resulted in a remarkable increase in the levels of IgG. The splenocytes of mice that received the combination of peptide and adjuvant displayed a noteworthy increase in IFN-?, IL-4, and granzyme B secretion. Additionally, their lymphocytes exhibited higher proliferation rates compared to the control group. Our data demonstrated that our vaccine could stimulate a robust immune response, making it a promising candidate for cancer prevention. However, clinical trials are necessary to assess its efficacy in humans.
dc.identifier.citation	Samman, N., Mohabatkar, H., Behbahani, M. ve Ganjlikhani Hakemi, M. (2024). Bioinformatics design of a peptide vaccine containing sarcoma antigen NY-SAR-35 epitopes against breast cancer and evaluation of its immunological function in BALB/c mouse model. PloS One, 19(6). http://dx.doi.org/10.1371/journal.pone.0306117
dc.identifier.doi	10.1371/journal.pone.0306117
dc.identifier.issn	1932-6203
dc.identifier.issue	6
dc.identifier.pmid	38923980
dc.identifier.scopus	2-s2.0-85196968513
dc.identifier.scopusquality	Q1
dc.identifier.uri	http://dx.doi.org/10.1371/journal.pone.0306117
dc.identifier.uri	https://hdl.handle.net/20.500.12511/12682
dc.identifier.volume	19
dc.identifier.wos	001259158900026	en_US
dc.identifier.wosquality	Q1
dc.indekslendigikaynak	Web of Science
dc.indekslendigikaynak	Scopus
dc.indekslendigikaynak	PubMed
dc.institutionauthor	Ganjlikhani Hakemi, Mazdak
dc.language.iso	en
dc.relation.ispartof	PloS One	en_US
dc.relation.publicationcategory	Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rights	Attribution 4.0 International	*
dc.rights	info:eu-repo/semantics/openAccess
dc.rights.uri	https://creativecommons.org/licenses/by/4.0/	*
dc.subject	NY-SAR-35
dc.subject	TSAs
dc.subject	TAAs
dc.subject	Tumor-Specific Antigens
dc.subject	Tumor-Associated Antigens
dc.title	Bioinformatics design of a peptide vaccine containing sarcoma antigen NY-SAR-35 epitopes against breast cancer and evaluation of its immunological function in BALB/c mouse model
dc.type	Article